Raymond Piatt1, David S Paul1, Robert H Lee1, Steven E McKenzie1, Leslie V Parise1, Dale O Cowley1, Brian C Cooley1, Wolfgang Bergmeier2. 1. From the McAllister Heart Institute, University of North Carolina, Chapel Hill (R.P., D.S.P., R.H.L., W.B.); Cardeza Foundation for Hematological Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA (S.E.M.); Department of Biochemistry and Biophysics (L.V.P., W.B.), Animal Models Core (D.O.C.), and Rodent Advanced Surgical Core (B.C.C.), University of North Carolina at Chapel Hill. 2. From the McAllister Heart Institute, University of North Carolina, Chapel Hill (R.P., D.S.P., R.H.L., W.B.); Cardeza Foundation for Hematological Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA (S.E.M.); Department of Biochemistry and Biophysics (L.V.P., W.B.), Animal Models Core (D.O.C.), and Rodent Advanced Surgical Core (B.C.C.), University of North Carolina at Chapel Hill. bergmeie@email.unc.edu.
Abstract
OBJECTIVE: The tight regulation of platelet adhesiveness, mediated by the αIIbβ3 integrin, is critical for hemostasis and prevention of thrombosis. We recently demonstrated that integrin affinity in platelets is controlled by the guanine nucleotide exchange factor, CalDAG-GEFI (CD-GEFI), and its target, RAP1. In this study, we investigated whether low-level expression of CD-GEFI leads to protection from thrombosis without pathological bleeding in mice. APPROACH AND RESULTS: Cdg1(low) mice were generated by knockin of human CD-GEFI cDNA into the mouse Cdg1 locus. CD-GEFI expression in platelets from Cdg1(low) mice was reduced by ≈90% when compared with controls. Activation of RAP1 and αIIbβ3 was abolished at low agonist concentrations and partially inhibited at high agonist concentrations in Cdg1(low) platelets. Consistently, the aggregation response of Cdg1(low) platelets was weaker than that of wild-type platelets, but more efficient than that observed in Cdg1(-/-) platelets. Importantly, Cdg1(low) mice were strongly protected from arterial and immune complex-mediated thrombosis, with only minimal impact on primary hemostasis. CONCLUSIONS: Together, our studies suggest the partial inhibition of CD-GEFI function as a powerful new approach to safely prevent thrombotic complications.
OBJECTIVE: The tight regulation of platelet adhesiveness, mediated by the αIIbβ3 integrin, is critical for hemostasis and prevention of thrombosis. We recently demonstrated that integrin affinity in platelets is controlled by the guanine nucleotide exchange factor, CalDAG-GEFI (CD-GEFI), and its target, RAP1. In this study, we investigated whether low-level expression of CD-GEFI leads to protection from thrombosis without pathological bleeding in mice. APPROACH AND RESULTS:Cdg1(low) mice were generated by knockin of humanCD-GEFI cDNA into the mouseCdg1 locus. CD-GEFI expression in platelets from Cdg1(low) mice was reduced by ≈90% when compared with controls. Activation of RAP1 and αIIbβ3 was abolished at low agonist concentrations and partially inhibited at high agonist concentrations in Cdg1(low) platelets. Consistently, the aggregation response of Cdg1(low) platelets was weaker than that of wild-type platelets, but more efficient than that observed in Cdg1(-/-) platelets. Importantly, Cdg1(low) mice were strongly protected from arterial and immune complex-mediated thrombosis, with only minimal impact on primary hemostasis. CONCLUSIONS: Together, our studies suggest the partial inhibition of CD-GEFI function as a powerful new approach to safely prevent thrombotic complications.
Authors: Guoying Zhang; Binggang Xiang; Shaojing Ye; Magdalena Chrzanowska-Wodnicka; Andrew J Morris; T Kent Gartner; Sidney W Whiteheart; Gilbert C White; Susan S Smyth; Zhenyu Li Journal: J Biol Chem Date: 2011-09-22 Impact factor: 5.157
Authors: Magdalena Chrzanowska-Wodnicka; Susan S Smyth; Simone M Schoenwaelder; Thomas H Fischer; Gilbert C White Journal: J Clin Invest Date: 2005-03 Impact factor: 14.808
Authors: Jill R Crittenden; Wolfgang Bergmeier; Yanyu Zhang; Crystal L Piffath; Yuqiong Liang; Denisa D Wagner; David E Housman; Ann M Graybiel Journal: Nat Med Date: 2004-08-29 Impact factor: 53.440
Authors: Timothy J Stalker; Elizabeth A Traxler; Jie Wu; Kenneth M Wannemacher; Samantha L Cermignano; Roman Voronov; Scott L Diamond; Lawrence F Brass Journal: Blood Date: 2013-01-09 Impact factor: 22.113
Authors: Brian G Petrich; Patrizia Marchese; Zaverio M Ruggeri; Saskia Spiess; Rachel A M Weichert; Feng Ye; Ralph Tiedt; Radek C Skoda; Susan J Monkley; David R Critchley; Mark H Ginsberg Journal: J Exp Med Date: 2007-12-17 Impact factor: 14.307
Authors: Robert H Lee; Tomohiro Kawano; Steven P Grover; Vanthana Bharathi; David Martinez; Dale O Cowley; Nigel Mackman; Wolfgang Bergmeier; Silvio Antoniak Journal: J Thromb Haemost Date: 2021-11-10 Impact factor: 5.824
Authors: David S Paul; Caterina Casari; Congying Wu; Raymond Piatt; Swetha Pasala; Robert A Campbell; Kathryn O Poe; Dorsaf Ghalloussi; Robert H Lee; Jeremy D Rotty; Brian C Cooley; Kellie R Machlus; Joseph E Italiano; Andrew S Weyrich; James E Bear; Wolfgang Bergmeier Journal: Blood Adv Date: 2017-08-08
Authors: Muzaddid Sarker; Ardeshir Goliaei; Florence Golesi; Marjorie Poggi; Aaron A Cook; Mohammad A I Khan; Brenda R Temple; Lucia Stefanini; Matthias Canault; Wolfgang Bergmeier; Sharon L Campbell Journal: J Thromb Haemost Date: 2019-12-30 Impact factor: 5.824
Authors: Lucia Stefanini; Robert H Lee; David S Paul; Ellen C O'Shaughnessy; Dorsaf Ghalloussi; Christopher I Jones; Yacine Boulaftali; Kathryn O Poe; Raymond Piatt; Dan O Kechele; Kathleen M Caron; Klaus M Hahn; Jonathan M Gibbins; Wolfgang Bergmeier Journal: Blood Date: 2018-08-21 Impact factor: 22.113
Authors: Amrita Desai; Wolfgang Bergmeier; Mathias Canault; Marie-Christine Alessi; David S Paul; Paquita Nurden; Xavier Pillois; Wenche Jy; Yeon S Ahn; Alan T Nurden Journal: Res Pract Thromb Haemost Date: 2017-06-20